CD274 and non-small cell lung carcinoma: The pooled analysis of studies KEYNOTE-010, -024, and -042 was conducted to evaluate the efficacy and safety of pembrolizumab monotherapy versus chemotherapy in elderly patients (≥75 years) with advanced, PD-L1 positive NSCLC [14].